A Phase I Dose Escalation Study of Intratumoral or Intravenous Herpes Simplex Virus-1 Mutant HSV1716 in Patients With Refractory Non-Central Nervous System (Non-CNS) Solid Tumors

Trial Profile

A Phase I Dose Escalation Study of Intratumoral or Intravenous Herpes Simplex Virus-1 Mutant HSV1716 in Patients With Refractory Non-Central Nervous System (Non-CNS) Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 May 2017

At a glance

  • Drugs HSV 1716 (Primary) ; HSV 1716 (Primary)
  • Indications Ewing's sarcoma; Nerve sheath neoplasms; Neuroblastoma; Osteosarcoma; Rhabdomyosarcoma; Sarcoma; Soft tissue sarcoma; Solid tumours; Wilms' tumour
  • Focus Adverse reactions
  • Most Recent Events

    • 11 May 2017 Results (n=9) published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 30 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 30 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top